Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

Lung cancer is the world's leading cause of cancer death and shows strong ancestry
disparities. By sequencing and assembling a large genomic and transcriptomic dataset of …

Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

Importance Targeting oncogenic drivers (genomic alterations critical to cancer development
and maintenance) has transformed the care of patients with lung adenocarcinomas. The …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

Small cell lung cancers (SCLCs) and extrapulmonary small cell cancers (SCCs) are very
aggressive tumors arising de novo as primary small cell cancer with characteristic genetic …

Abstract The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …

Introduction Tumor size is a known prognostic factor for early stage non–small-cell lung
cancer (NSCLC), but its significance in node-positive and locally invasive NSCLC has not …